Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 571

1.

CaseBook challenges: Managing gout, hyperuricemia and comorbidities -- dialogue with the experts.

Bakris GL, Doghramji PP, Keenan RT, Silber SH.

Am J Med. 2014 Jan;127(1):S1. doi: 10.1016/j.amjmed.2013.11.001. Epub 2013 Nov 19.

PMID:
24268074
2.

Casebook consults: improving outcomes in gout (multimedia activity).

Doghramji PP, Mandell BF, Pope RS.

Am J Med. 2012 Aug;125(8):S1. doi: 10.1016/j.amjmed.2012.06.002.

PMID:
22840678
3.

Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.

Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C.

J Rheumatol. 2009 Jun;36(6):1273-82. doi: 10.3899/jrheum.080814. Epub 2009 Mar 13.

PMID:
19286847
4.

The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age.

Jackson RL, Hunt B, MacDonald PA.

BMC Geriatr. 2012 Mar 21;12:11. doi: 10.1186/1471-2318-12-11.

5.

Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.

Wortmann RL, Macdonald PA, Hunt B, Jackson RL.

Clin Ther. 2010 Dec;32(14):2386-97. doi: 10.1016/j.clinthera.2011.01.008.

PMID:
21353107
6.

Safety of urate-lowering therapies: managing the risks to gain the benefits.

Keenan RT.

Rheum Dis Clin North Am. 2012 Nov;38(4):663-80. doi: 10.1016/j.rdc.2012.08.008. Epub 2012 Sep 7. Review.

PMID:
23137576
7.

Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.

Hatoum H, Khanna D, Lin SJ, Akhras KS, Shiozawa A, Khanna P.

Postgrad Med. 2014 Mar;126(2):65-75. doi: 10.3810/pgm.2014.03.2741.

PMID:
24685969
8.

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.

Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, Lademacher C.

Arthritis Res Ther. 2010;12(2):R63. doi: 10.1186/ar2978. Epub 2010 Apr 6.

9.

Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.

Chohan S, Becker MA, MacDonald PA, Chefo S, Jackson RL.

Arthritis Care Res (Hoboken). 2012 Feb;64(2):256-61. doi: 10.1002/acr.20680.

10.

What do I need to know about gout?

Becker MA, Ruoff GE.

J Fam Pract. 2010 Jun;59(6 Suppl):S1-8. Review.

PMID:
20544070
11.

Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.

Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N.

Arthritis Rheum. 2008 Nov 15;59(11):1540-8. doi: 10.1002/art.24209.

12.

An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.

Huang X, Du H, Gu J, Zhao D, Jiang L, Li X, Zuo X, Liu Y, Li Z, Li X, Zhu P, Li J, Zhang Z, Huang A, Zhang Y, Bao C.

Int J Rheum Dis. 2014 Jul;17(6):679-86. doi: 10.1111/1756-185X.12266. Epub 2014 Jan 28.

PMID:
24467549
13.

A world of hurt: failure to achieve treatment goals in patients with gout requires a paradigm shift.

Khanna P, Khanna D, Storgard C, Baumgartner S, Morlock R.

Postgrad Med. 2016 Jan;128(1):34-40. doi: 10.1080/00325481.2016.1113840. Epub 2015 Nov 17.

PMID:
26578028
14.

Gout Study Group: update on hyperuricemia and gout.

Terkeltaub R, Zelman D, Scavulli J, Perez-Ruiz F, Lioté F.

Joint Bone Spine. 2009 Jul;76(4):444-6. doi: 10.1016/j.jbspin.2009.05.006. Epub 2009 Jun 25. No abstract available.

PMID:
19559637
15.

Limitations of the Current Standards of Care for Treating Gout and Crystal Deposition in the Primary Care Setting: A Review.

Keenan RT.

Clin Ther. 2017 Feb;39(2):430-441. doi: 10.1016/j.clinthera.2016.12.011. Epub 2017 Jan 11. Review.

16.

Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.

Ernst ME, Fravel MA.

Clin Ther. 2009 Nov;31(11):2503-18. doi: 10.1016/j.clinthera.2009.11.033. Review.

PMID:
20109996
17.

[Establishment of therapeutic goal and plan of gout and asymptomatic hyperuricemia].

Fujimori S.

Nihon Rinsho. 2008 Apr;66(4):729-35. Review. Japanese.

PMID:
18409523
18.

Urate-lowering therapy for gout: focus on febuxostat.

Love BL, Barrons R, Veverka A, Snider KM.

Pharmacotherapy. 2010 Jun;30(6):594-608. doi: 10.1592/phco.30.6.594. Review.

PMID:
20500048
19.

Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis.

Ye P, Yang S, Zhang W, Lv Q, Cheng Q, Mei M, Luo T, Liu L, Chen S, Li Q.

Clin Ther. 2013 Feb;35(2):180-9. doi: 10.1016/j.clinthera.2012.12.011. Epub 2013 Jan 16. Review.

PMID:
23332451
20.

Treatment of hyperuricemia, gout and other crystalline arthritidies.

Lioté F.

Reumatismo. 2012 Jan 19;63(4):276-83. doi: 10.4081/reumatismo.2011.276. Review.

PMID:
22303534

Supplemental Content

Support Center